Demographics and clinical characteristics at baseline of double-blind study for patients who later entered the longterm extension. Values are mean ± SD unless otherwise stated.
| Characteristics | Abatacept + DMARD*, n = 218 | Placebo + DMARD*, n = 99 |
|---|---|---|
| Age, yrs | 53.1 ± 12.1 | 52.7 ± 10.9 |
| Women, n (%) | 167 (76.6) | 79 (79.8) |
| White, n (%) | 211 (96.8) | 92 (92.9) |
| Duration of RA, yrs | 12.1 ± 8.6 | 11.0 ± 8.7 |
| Tender joints, n | 31.5 ± 13.3 | 32.3 ± 13.7 |
| Swollen joints, n | 22.4 ± 10.4 | 22.2 ± 10.5 |
| DAS28 (CRP) | 6.5 ± 0.8 | 6.5 ± 0.8 |
| Physical function (HAQ-DI score) | 1.8 ± 0.6 | 1.8 ± 0.6 |
| Patient pain assessment (VAS 100 mm) | 70.6 ± 19.4 | 68.2 ± 19.4 |
| Patient global assessment (VAS 100 mm) | 68.6 ± 19.3 | 68.0 ± 21.0 |
| Physician global assessment (VAS 100 mm) | 67.7 ± 17.8 | 65.1 ± 17.6 |
| Physical component summary | 27.7 ± 6.8† | 28.0 ± 6.8 |
| Mental component summary | 41.4 ± 12.6† | 43.5 ± 12.1 |
| CRP, mg/dl | 4.6 ± 3.9 | 3.3 ± 3.1 |
↵* Study groups represent treatment received in the 6-month double-blind period.
↵† n = 213. DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis; DAS28: Disease Activity Score 28 joints; HAQ-DI: Health Assessment Questionnaire-Disability Index; VAS: visual analog scale; CRP: C-reactive protein.